Publication date: Nov 26, 2019
The purpose of this study is to generate hypotheses regarding the safety, efficacy, and immunological impact of cladribine tablets after treatment with natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (active SPMS).
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Cladribine |
| drug | DRUGBANK | Natalizumab |
| disease | MESH | relapsing-remitting multiple sclerosis |
| disease | MESH | secondary progressive multiple sclerosis |
| disease | MESH | Diagnosis |
| disease | MESH | relapses |
| drug | DRUGBANK | Methylergometrine |
| disease | MESH | Syndrome |
| disease | MESH | hypersensitivity |
| drug | DRUGBANK | Mitoxantrone |
| drug | DRUGBANK | Azathioprine |
| drug | DRUGBANK | Methotrexate |
| drug | DRUGBANK | Cyclophosphamide |
| drug | DRUGBANK | Immune Globulin Human |
| disease | MESH | hepatitis C |
| pathway | KEGG | Hepatitis C |
| drug | DRUGBANK | Hepatitis B Vaccine (Recombinant) |
| disease | MESH | tuberculosis |
| pathway | KEGG | Tuberculosis |
| disease | MESH | latent tuberculosis |
| drug | DRUGBANK | Gold |
| drug | DRUGBANK | Ciclosporin |
| disease | MESH | malignancy |
| disease | MESH | fructose intolerance |
| drug | DRUGBANK | Gadolinium |
| disease | MESH | contraindication |
| disease | MESH | renal |
| disease | MESH | renal insufficiency |
| disease | MESH | Multiple Sclerosis |